Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors

Brain Research

Volumn 1279, Issue , 2009, Pages 189-196

  Kunitachi, Shinsui ^a   Fujita, Yuko ^a   Ishima, Tamaki ^a   Kohno, Mami ^a   Horio, Mao ^a   Tanibuchi, Yuko ^a,c   Shirayama, Yukihiko ^b   Iyo, Masaomi ^c   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cognition; NMDA receptor; Phencyclidine; Schizophrenia; Sigma 1 receptor

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; DONEPEZIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PHYSOSTIGMINE; SIGMA 1 OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOGNITION;

ANALYSIS OF VARIANCE; ANIMALS; ANISOLES; BRAIN; CELL MEMBRANE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INDANS; MALE; MICE; MICE, INBRED ICR; PHENCYCLIDINE; PHYSOSTIGMINE; PIPERIDINES; PROPYLAMINES; RECEPTORS, SIGMA; RECOGNITION (PSYCHOLOGY); TRITIUM;

MUS;

EID: 67649398772     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.05.004     Document Type: Article

References (62)

1. Akhondzadeh S., Gerami M., Noroozian M., Karamghadiri N., Ghoreishi A., Abbasi S.H., and Rezazadeh S.A. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 (2008) 1810-1815
2. Anastasio N.C., and Johnson K.M. Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J. Neurochem. 104 (2008) 1210-1218
3. Bermack J.E., and Debonnel G. The role of sigma receptors in depression. J. Pharmacol. Sci. 97 (2005) 317-336
4. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
5. Buchanan R.W., Summerfelt A., Tek C., and Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res. 59 (2003) 29-33
6. Chung Y.G., Lee C.R., Park T.W., Yang K.H., and Kim K.W. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J. Biol. Psychiatry 10 (2009) 156-162
7. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3 (1996) 241-253
8. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174 (2004) 32-38
9. Csernansky J.G., Martin M., Shah R., Bertchume A., Colvin J., and Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 30 (2005) 2135-2143
10. Fagerlund B., Soholm B., Fink-Jensen A., Lublin H., and Glenthoj B.Y. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 30 (2007) 3-12
11. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
12. Freudenreich O., Herz L., Deckersbach T., Evins A.E., Henderson D.C., Cather C., and Goff D.C. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 181 (2005) 358-363
13. Friedman J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174 (2004) 45-53
14. Friedman J.I., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., White L., Parrella M., and Davis K.L. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51 (2002) 349-357
15. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., and Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56 (2004) 301-307
16. Guitart X., Codony X., and Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 174 (2004) 301-319
17. Hashimoto, K., in press. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med. Chem.
18. Hashimoto K., and London E.D. Imaging sigma receptors and cerebral responses to sigma drugs. In: Itzhak Y. (Ed). Sigma Receptors (1994), Academic. Press, New York 225-242
19. Hashimoto K., and London E.D. Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur. J. Pharmacol. 273 (1995) 307-310
20. Hashimoto K., and Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. 12 (2006) 3857-3876
21. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., and Iyo M. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60 (2003) 572-576
22. Hashimoto K., Okamura N., Shimizu E., and Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem-CNS.Agents 4 (2004) 147-154
23. Hashimoto K., Fujita Y., Shimizu E., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 519 (2005) 114-117
24. Hashimoto K., Shimizu E., and Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev. 1 (2005) 151-163
25. Hashimoto K., Fujita Y., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 32 (2007) 514-521
26. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., Tsukada H., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 63 (2008) 92-97
27. Hayashi T., and Su T.P. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18 (2004) 269-284
28. 2+ signaling and cell survival. Cell 131 (2007) 596-610
29. 4 sites in schizophrenic brains. Eur. J. Pharmacol. 314 (1996) R3-R5
30. 11C]SA4503. Biol. Psychiatry 62 (2007) 878-883
31. 3 receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 (2008) 1656-1659
32. Ishima T., Fujita Y., Kohno M., Kunitachi S., Horio M., Takatsu Y., Minase T., Tanibuchi Y., Hagiwara H., Iyo M., and Hashimoto K. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open. Clin. Chem. J. 2 (2009) 7-11
33. 2-like receptors. Ann. Nucl. Med. 20 (2006) 569-573
34. Iyo M., Shirayama Y., Watanabe H., Fujisaki M., Miyatake R., Fukami G., Shiina A., Nakazato M., Shiraishi T., Ookami T., and Hashimoto K. Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 (2008) 1072-1073
35. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
36. Javitt D.C., Balla A., Burch S., Suckow R., Xie S., and Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 29 (2004) 300-307
37. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
38. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., and Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci. Lett. 260 (1999) 5-8
39. Keefe R.S., Malhotra A.K., Meltzer H.Y., Kane J.M., Buchanan R.W., Murthy A., Sovel M., Li C., and Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33 (2008) 1217-1228
40. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., and Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7 (1999) 125-143
41. Kurtz M.M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr. Res. 74 (2005) 15-26
42. MacEwan G.W., Ehmann T.S., Khanbhai I., and Wrixon C. Donepezil in schizophrenia-is it helpful? An experimental design case study. Acta Psychiatr. Scand. 104 (2001) 469-472
43. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav. Pharmacol. 14 (2003) 533-544
44. Mattson M.P., and Chan S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci. 17 (2001) 205-224
45. Maurice T., Urani A., Phan V.L., and Romieu P. The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res. Rev. 37 (2001) 116-132
46. Maurice T., Meunier J., Feng B., Ieni J., and Monaghan D.T. Interaction with sigma-1 protein, but not N-methyl-d-aspartate receptor, is involved in the pharmacological activity of donepezil. J. Pharmacol. Exp. Ther. 317 (2006) 606-614
47. Meunier J., Ieni J., and Maurice T. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J. Pharmacol. Exp. Ther. 317 (2006) 1307-1319
48. Meunier J., Ieni J., and Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid-β25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br. J. Pharmacol. 149 (2006) 998-1012
49. Monnet F.P., and Maurice T. The sigma-1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects. J. Pharmacol. Sci. 100 (2006) 93-118
50. Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B.A., and Yuan J. Caspase-12 mediated ebdoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403 (2000) 98-103
51. Narita N., Hashimoto K., Tomitaka S., and Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 307 (1996) 117-119
52. Okuyama S., and Nakazato A. NE-100: a novel sigma receptor antagonist. CNS Drug Rev. 2 (1996) 226-237
53. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
54. Risch S.C., McGurk S., Horner M.D., Nahas Z., Owens S.D., Molloy M., Gilliard C., Christie S., Markowitz J.S., DeVane C.L., Mintzer J., and George M.S. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 7 (2001) 105-110
55. Risch S.C., Horner M.D., McGurk S., Palecko S., Markowitz J.S., Nahas Z., and DeVane C.L. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr. Res. 93 (2007) 131-135
56. Seltzer B. Donepezil: an update. Expert Opin. Pharmacother. 8 (2007) 1011-1023
57. Senda T., Matsuno K., Kobayashi T., and Mita S. Reduction of the scopolamine-induced impairment of passive-avoidance performance by sigma receptor agonist in mice. Physiol. Behav. 61 (1997) 257-264
58. Shibuya H., Mori H., and Toru M. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Neurochem. Res. 17 (1992) 983-990
59. Simpson M.D., Slater P., Royston M.C., and Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr. Res. 6 (1991) 41-48
60. Su T.P., and Hayashi T. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. 10 (2003) 2073-2080
61. Tugal O., Yazici K.M., Anil Yagcioglu A.E., and Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7 (2004) 117-123
62. Weissman A.D., Casanova M.F., Kleinman J.E., London E.D., and De Souza E.B. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol. Psychiatry 29 (1991) 41-54